title: In vitro characterization of Acanthamoeba castellanii cytopathic effect.
abstract: This study examined the mechanism of the cytopathic effect (CPE) of Acanthamoeba castellanii on human target cells. Pathogenic Acanthamoeba trophozoites were incubated with human ocular melanoma (OCM1) cells for 30 min, 1 hr, and 3 hr. The amoebae were treated with a calcium ionophore (A23187), phorbol myristate ester (PMA), calcium channel blocker (Bepridil), cytochalasin D, and L-leucyl-L-leucine methyl ester (leu-leu-OMe). Cytolysis was quantified using a spectrophotometric assay. Cocultures of amoeba and cells were also observed by transmission electron microscopy at 1, 2, and 3 hr. Results show that trophozoites formed pseudopodia that made intimate contact with the target cell membrane. Neither amebostomes nor phagocytosis was seen. The calcium ionophore A23187 increased the cytopathic effect of the trophozoites on the cultured OCM1. In contrast, cytochalasin D, Bepridil, and PMA reduced the cytopathic effect. Leu-leu-OMe did not result in killing of Acanthamoeba trophozoites. The results suggest that the cytopathic effect of Acanthamoeba trophozoites involves calcium channels and cytoskeletal elements. There was no evidence of trogocytosis or phagocytosis as sometimes occurs in cytolysis by other free-living amoeba. Although Acanthamoeba-mediated CPE in some ways resembles CPE produced by cytotoxic lymphocytes, the mechanisms are not identical.
authors.affiliation: Division of Comparative Medicine, UT Southwestern Medical Center at Dallas 75235-9037, USA.
authors.forename: W M
authors.initials: WM
authors.lastname: Taylor
authors.forename: M S
authors.initials: MS
authors.lastname: Pidherney
authors.forename: H
authors.initials: H
authors.lastname: Alizadeh
authors.forename: J Y
authors.initials: JY
authors.lastname: Niederkorn
mesh_terms: D000048:Acanthamoeba / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D000818:Animals; D015764:Bepridil / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D020789:Cathepsin C; D002470:Cell Survival; D015638:Cytochalasin D / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects / Q000502:physiology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004151:Dipeptides / Q000494:pharmacology; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects; D008545:Melanoma / Q000469:parasitology*; D008854:Microscopy, Electron; D011493:Protein Kinase C / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014604:Uveal Neoplasms / Q000469:parasitology*
chemical_list: D015220:Calcium Channels; D004151:Dipeptides; D007166:Immunosuppressive Agents; C045139:leucyl-leucine-methyl ester; D015638:Cytochalasin D; D000001:Calcimycin; D015764:Bepridil; D011493:Protein Kinase C; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D020789:Cathepsin C; D013755:Tetradecanoylphorbol Acetate